当前位置： SCI文献检索 > Clinical Genitourinary Cancer期刊下所有文献 > Effect of Diphosphonates on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer.

Effect of Diphosphonates on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer.

Abstract：

:Patients receiving androgen deprivation therapy are associated with increasing loss of bone mineral density (BMD) and higher risk of skeletal-related events. We reviewed and analyzed the influence of diphosphonates on BMD change. A systemic literature research was conducted in PubMed and related bibliographies. The focus of data extraction was BMD percentage change of lumbar spine, total hip, and femoral neck after 12 months. Standardized mean difference (SMD) was pooled with the random-effects model, and metaregression and subgroup analysis were performed to explore heterogeneity. Nine articles (n = 920) were included and finally analyzed after screening 118 articles. We found significant improvement in BMD percentage changes of the lumbar spine, total hip, and femoral neck at 1 year (respectively, SMD = 6.379, 95% confidence interval [CI] = 3.740-9.018, P < .001, I2 = 98.8%, P < .001; SMD = 4.870, 95% CI, 2.256-7.485, P < .001, I2 = 98.9%, P < .001; SMD = 3.634, 95% CI, 1.989-5.279, P < .001, I2 = 97.3%, P < .001). In individual variable metaregression analysis, application zoledronic acid or not showed a statistically significant influence on BMD percentage change of total hip (P = .018). In subgroup analyses, both zoledronic acid and alendronate showed a significant improvement in BMD percentage changes. Diphosphonates significantly increased BMD percentage changes of the lumbar spine, total hip, and femoral neck in men receiving androgen deprivation therapy for prostate cancer. Patients with androgen deprivation therapy should be evaluated BMD loss, and timely therapy with diphosphonates may be an appropriate strategy to prevent osteoporosis.

journal_name

Clin Genitourin Cancer

journal_title

Clinical genitourinary cancer

authors

Wu C,Chen W,Huang X,Lin R,Wu J,Zhang X

doi

10.1016/j.clgc.2018.07.016

subject

Has Abstract

pub_date

2018-12-01 00:00:00

pages

e1243-e1250

issue

6

eissn

1558-7673

issn

1938-0682

pii

S1558-7673(18)30203-9

journal_volume

16

pub_type

杂志文章,meta分析,评审

相关文献

Clinical Genitourinary Cancer文献大全
  • Impact of Bladder Neck Involvement on Recurrence in Patients With Non-muscle-invasive Bladder Cancer: An Analysis Based on a Time-dependent Model.

    abstract：BACKGROUND:Tumor location in bladder neck has reported to be a prognostic factor for non-muscle-invasive bladder cancer (NMIBC). We investigated the impact of bladder neck involvement (BNI) on recurrence in NMIBC using time-dependent covariate analysis. PATIENTS AND METHODS:We enrolled 585 Japanese patients who underw...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.10.005

    authors： Waseda Y,Kobayashi S,Kanda E,Yokoyama M,Ishioka J,Matsuoka Y,Saito K,Fujii Y

    更新日期：2020-04-01 00:00:00

  • Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.

    abstract：:The use of sunitinib in dialysis patients is poorly described but is of clinical importance. We report 2 cases of patients receiving sunitinib for metastatic renal cell carcinoma while undergoing dialysis. The first patient is undergoing hemodialysis and, though responding to sunitinib, is having significant fatigue a...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.3816/CGC.2009.n.035

    authors： Vickers MM,Heng DY,Hemmelgarn B,Eigl BJ

    更新日期：2009-10-01 00:00:00

  • Cardiovascular and Metabolic Toxicity of Abiraterone in Castration-resistant Prostate Cancer: Post-marketing Experience.

    abstract：INTRODUCTION:Abiraterone improves survival in metastatic castration-resistant prostate cancer (mCRPC) but may result in the development or worsening of comorbid conditions. We assessed the course of these conditions in patients receiving abiraterone in clinical practice and compared outcomes with those in clinical tria...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.03.001

    authors： Tsao PA,Estes JP,Griggs JJ,Smith DC,Caram MEV

    更新日期：2019-06-01 00:00:00

  • Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma and End-stage Renal Disease at 2 Centers.

    abstract：INTRODUCTION:There is scarce information regarding nivolumab treatment for metastatic renal cell carcinoma (mRCC) in patients with end-stage renal disease (ESRD). This study investigated the safety and efficacy of nivolumab in patients with mRCC and ESRD. MATERIALS AND METHODS:This 2-center retrospective study evaluat...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clgc.2019.04.004

    authors： Tachibana H,Kondo T,Ishihara H,Takagi T,Tanabe K

    更新日期：2019-08-01 00:00:00

  • Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma.

    abstract：INTRODUCTION:In the first-line (1L) setting, pazopanib (PAZ) has been recommended by the National Comprehensive Cancer Network for the treatment of advanced renal cell carcinoma (aRCC). In 2018, immuno-oncology (IO) therapy became a commonly used 1L treatment option for aRCC. We report the real-world clinical outcomes ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clgc.2019.10.010

    authors： Cao X,Tang D,Ratto B,Poole A,Ravichandran S,Jin L,Gao W,Swallow E,Vogelzang NJ

    更新日期：2020-02-01 00:00:00

  • Impact of Prior Use of an Androgen Receptor-Axis-Targeted (ARAT) Agent With or Without Subsequent Taxane Therapy on the Efficacy of Another ARAT Agent in Patients With Metastatic Castration-Resistant Prostate Cancer.

    abstract：BACKGROUND:The objective of this study was to investigate whether the prior use of a novel androgen receptor-axis-targeted (ARAT) agent with or without subsequent taxane therapy could affect the efficacy of another ARAT agent in patients with metastatic castration-resistant prostate cancer (mCRPC). PATIENTS AND METHOD...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2016.07.005

    authors： Miyake H,Hara T,Ozono S,Fujisawa M

    更新日期：2017-04-01 00:00:00

  • Expression of microRNAs in the urine of patients with bladder cancer.

    abstract：UNLABELLED:We quantified the urine sediment and supernatant levels of microRNA (miRNA) targets related to epithelial-mesenchymal transition in 51 patients with bladder cancer and in 24 controls. We found that patients with bladder cancer had depressed levels of the miR-200 family, miR-192, and miR-155 in urinary sedime...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2012.01.001

    authors： Wang G,Chan ES,Kwan BC,Li PK,Yip SK,Szeto CC,Ng CF

    更新日期：2012-06-01 00:00:00

  • Upper urinary tract transitional cell carcinoma: is there a best?

    abstract：BACKGROUND:This study aimed to determine the prognostic and risk factors for bladder and systemic recurrence after nephroureterectomy (NU) in patients with upper urinary tract (UUT) transitional cell carcinoma (TCC). PATIENTS AND METHODS:Data from 101 patients with nonmetastatic UUT TCC who underwent NU between 1987 a...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2012.08.009

    authors： Gunay LM,Akdogan B,Koni A,Inci K,Bilen CY,Ozen H

    更新日期：2013-03-01 00:00:00

  • Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.

    abstract：BACKGROUND:In the phase III axitinib second-line (AXIS) trial, axitinib significantly prolonged progression-free survival (PFS) versus sorafenib in patients with previously treated metastatic renal cell carcinoma (mRCC). Analyses of associations between germline single-nucleotide polymorphisms (SNPs) and outcomes are r...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.clgc.2015.02.007

    authors： Escudier B,Rini BI,Motzer RJ,Tarazi J,Kim S,Huang X,Rosbrook B,English PA,Loomis AK,Williams JA

    更新日期：2015-08-01 00:00:00

  • Location of Metastases in Contemporary Prostate Cancer Patients Affects Cancer-Specific Mortality.

    abstract：PURPOSE:To quantify the prognostic effect of the location of prostate cancer (PCa) metastases on cancer-specific mortality (CSM) and the rate of other-cause mortality (OCM) in contemporary newly diagnosed metastatic PCa (mPCa) patients. PATIENTS AND METHODS:Within the Surveillance Epidemiology and End Results database...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2018.05.016

    authors： Mazzone E,Preisser F,Nazzani S,Tian Z,Bandini M,Gandaglia G,Fossati N,Soulières D,Graefen M,Montorsi F,Shariat SF,Saad F,Briganti A,Karakiewicz PI

    更新日期：2018-10-01 00:00:00

  • The Prognostic Value of Tumor Regression Grades Combined With TNM Classification in Patients With Muscle-Invasive Bladder Cancer Who Underwent Neoadjuvant Chemotherapy Followed by Radical Cystectomy.

    abstract：INTRODUCTION:Tumor regression grades (TRGs) quantify the pathologic response to neoadjuvant chemotherapy (NAC). The aim of the study was to investigate the prognostic value of TRGs in combination with the TNM classification in an independent cohort of patients with muscle-invasive bladder cancer (MIBC) treated with NAC...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.09.003

    authors： Gronostaj K,Czech AK,Fronczek J,Drobniak A,Okon K,Chlosta PL,Szczeklik W

    更新日期：2019-12-01 00:00:00

  • Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents.

    abstract：BACKGROUND:Several agents have demonstrated an overall survival (OS) benefit in patients with metastatic castration-resistant prostate cancer (mCRPC); however, the optimal sequencing of these therapies is unknown as a result of a lack of prospective randomized controlled trials. This retrospective study aimed to identi...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clgc.2018.02.016

    authors： Angelergues A,Efstathiou E,Gyftaki R,Wysocki PJ,Lainez N,Gonzalez I,Castellano DE,Ozguroglu M,Carbonero IG,Flechon A,Borrega P,Guillot A,Balea BC,Le Moulec S,Esteban E,Munarriz J,Rubio G,Birtle AJ,Delanoy N,Bellmunt

    更新日期：2018-08-01 00:00:00

  • Identification of Differential Patterns of Oxidative Biomarkers in Prostate Cancer Progression.

    abstract：INTRODUCTION:Oxidative stress has been found to be associated with the progression of prostate cancer (PCa); however, human studies which identify differential roles of each oxidation pathway in PCa progression are lacking. We aimed to identify which oxidative stress markers, specifically lipid and global oxidation and...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.09.014

    authors： Wu T,Kasper S,Wong RM,Bracken B

    更新日期：2020-04-01 00:00:00

  • Prostate Cancer in Patients With High Prostate-Specific Antigen Levels but Otherwise Very-Low-Risk Disease Behaves Like Prostate Cancer in High-Risk Patients.

    abstract：INTRODUCTION:Rarely, patients with prostate cancer present with prostate-specific antigen (PSA) scores > 20 ng/mL but with otherwise very-low-risk disease. Oncologists have debated whether the malignancies in these patients behave more comparably to low-risk or high-risk disease. Our objective was to elucidate the beha...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2016.10.003

    authors： Gestaut MM,Pruszynski JE,Swanson GP

    更新日期：2017-08-01 00:00:00

  • What Have Patients Been Hearing From Providers Since the 2012 USPSTF Recommendation Against Routine Prostate Cancer Screening?

    abstract：BACKGROUND:In this study we aimed to determine the relationship between prostate-specific antigen (PSA)-related information obtained from the provider and PSA test uptake. With recent focus on patient-provider communication (PC) and the guidelines recommending against PSA tests for prostate cancer (PCa), PC regarding t...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2017.05.002

    authors： Haider MR,Qureshi ZP,Horner R,Friedman DB,Bennett C

    更新日期：2017-12-01 00:00:00

  • Associations Between Prostate Volume and Oncologic Outcomes in Men Undergoing Focal Cryoablation of the Prostate.

    abstract：INTRODUCTION:The purpose of this study was to assess the relationship of total prostate volume (TPV) and oncologic outcomes following focal prostate cryoablation. MATERIALS AND METHODS:A query of the Cryo On-Line Database (COLD) registry for men who underwent primary focal prostate cryoablation revealed 829 patients w...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clgc.2017.10.009

    authors： Elshafei A,Tay KJ,Kara O,Malkoc E,Nyame Y,Arora H,Hatem A,Patel SA,Lugnani F,Polascik TJ,Jones JS

    更新日期：2018-04-01 00:00:00

  • Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line Chemotherapy.

    abstract：BACKGROUND:Venous thromboembolic events (VTEs) frequently occur in cancer patients. Risk assessment models (RAMs) for cancer-associated thrombosis have been proposed. However, advanced urinary tract cancer (aUTC) was not adequately represented in these models. We studied the incidence of VTEs, the risk factors, and the...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.12.021

    authors： Bamias A,Tzannis K,Dimitriadis I,Tsironis G,Papatheorodidi AM,Tsiara A,Fragkoulis C,Xirokosta A,Barbarousi D,Papadopoulos G,Zakopoulou R,Varkarakis I,Mitsogiannis I,Adamakis I,Alamanis C,Stravodimos K,Papatsoris AG,Dell

    更新日期：2020-08-01 00:00:00

  • Human immunodeficiency virus--associated renal cell carcinoma: a transatlantic case series.

    abstract：OBJECTIVE:The spectrum of diseases associated with human immunodeficiency virus (HIV) infection has changed dramatically following the introduction of highly active antiretroviral therapy (HAART). Non-AIDS-defining cancers, including renal cell carcinoma (RCC), are being recognized increasingly in this population. Our ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.3816/CGC.2008.n.013

    authors： Gaughan EM,Dezube BJ,Aboulafia D,Bower M,Stebbing J,Powles T,Pantanowitz L

    更新日期：2008-09-01 00:00:00

  • Serum Proteomics on the Basis of Discovery of Predictive Biomarkers of Response to Androgen Deprivation Therapy in Advanced Prostate Cancer.

    abstract：BACKGROUND:We investigated the serum proteome of hormone-sensitive prostate cancer patients to determine candidate biomarkers associated with androgen deprivation therapy (ADT) efficacy. PATIENTS AND METHODS:Serum proteomes generated using isobaric mass tags for relative and absolute quantitation were analyzed using r...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.03.006

    authors： Kohli M,Oberg AL,Mahoney DW,Riska SM,Sherwood R,Zhang Y,Zenka RM,Sahasrabudhe D,Qin R,Zhang S

    更新日期：2019-08-01 00:00:00

  • Prognostic Value of Lactate Dehydrogenase in Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.

    abstract：:The purpose of this study was to assess the prognostic value of lactate dehydrogenase (LDH) in patients with metastatic prostate cancer (PC). A systematic review and meta-analysis was performed in March 2019 according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Studies were deem...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,meta分析

    doi：10.1016/j.clgc.2019.07.009

    authors： Mori K,Kimura S,Parizi MK,Enikeev DV,Glybochko PV,Seebacher V,Fajkovic H,Mostafaei H,Lysenko I,Janisch F,Egawa S,Shariat SF

    更新日期：2019-12-01 00:00:00

  • Identification of Candidates for Active Surveillance: Should We Change the Current Paradigm?

    abstract：:Active surveillance (AS) has been claimed to avoid overtreatment of prostate cancer (PCa). It remains unclear which patients may benefit from AS. One way to clarify this is to improve the definition of insignificant PCa. PSA and Gleason score--the basic instruments used to select patients for AS--suffer from systemati...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clgc.2015.06.001

    authors： Alcover J,Filella X

    更新日期：2015-12-01 00:00:00

  • Rates of Positive Surgical Margins and Their Effect on Cancer-specific Mortality at Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer.

    abstract：BACKGROUND:The objective of this study was to investigate positive surgical margin (PSM) rates in patients with prostate cancer treated with radical prostatectomy (RP) and assess PSM impact on cancer-specific mortality (CSM). PATIENTS AND METHODS:Within the Surveillance, Epidemiology, and End Results (SEER) database (...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2018.09.024

    authors： Preisser F,Mazzone E,Knipper S,Nazzani S,Bandini M,Shariat SF,Tian Z,Saad F,Montorsi F,Zorn KC,Graefen M,Tilki D,Karakiewicz PI

    更新日期：2019-02-01 00:00:00

  • Outcomes and tolerance of human immunodeficiency virus--positive U.S. veterans undergoing dose-escalated external beam radiotherapy for localized prostate cancer.

    abstract：INTRODUCTION:There are little data on the outcomes and tolerance, as well as the impact on the CD4 counts, of human immunodeficiency virus (HIV)-positive patients with prostate cancer who undergo high-dose external beam radiotherapy. MATERIALS AND METHODS:We identified 15 HIV-positive patients with prostate cancer who...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2013.07.008

    authors： Schreiber D,Chhabra A,Rineer J,Nabhani T,Katsoulakis E,Morkos R,Rotman M,Schwartz D

    更新日期：2014-04-01 00:00:00

  • Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study.

    abstract：BACKGROUND:We investigated the activity of lenalidomide, which has antiangiogenic, antineoplastic, and immunomodulatory properties, in chemotherapy-naive, castration-resistant prostate cancer (CRPC) patients. PATIENTS:Patients received 25 mg/d lenalidomide for 21 days in 28-day cycles, until disease progression or una...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2013.09.001

    authors： Nabhan C,Patel A,Villines D,Tolzien K,Kelby SK,Lestingi TM

    更新日期：2014-02-01 00:00:00

  • Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the Netherlands.

    abstract：BACKGROUND:The purpose of this study was to determine generic, cancer-specific, and prostate cancer-specific health-related quality of life (HRQoL), pain and changes over time in patients with metastatic castration-resistant prostate cancer (mCRPC) in daily practice. PATIENTS AND METHODS:PRO-CAPRI is an observational,...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.11.015

    authors： Kuppen MCP,Westgeest HM,van den Eertwegh AJM,Coenen JLLM,van Moorselaar RJA,van den Berg P,Geenen MM,Mehra N,Hendriks MP,Lampe MI,van de Luijtgaarden ACM,Peters FPJ,Roeleveld TA,Smilde TJ,de Wit R,van Oort IM,Gerritsen WR

    更新日期：2020-06-01 00:00:00

  • Lymph Node Fluorescence During Robot-Assisted Radical Prostatectomy With Indocyanine Green: Prospective Dosing Analysis.

    abstract：OBJECTIVE:To prospectively assess the ideal dosing and the value of fluorescent sentinel lymph node (LN) detection with indocyanine green (ICG) for the detection of LN metastases in intermediate- and high-risk patients undergoing robot-assisted prostatectomy and extended pelvic LN dissection (ePLND). PATIENTS AND METH...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2016.10.014

    authors： Chennamsetty A,Zhumkhawala A,Tobis SB,Ruel N,Lau CS,Yamzon J,Wilson TG,Yuh BE

    更新日期：2017-08-01 00:00:00

  • Greatest Percentage Involved Core Length and Risk of Clinically Significant Prostate-Specific Antigen Failure After Radical Prostatectomy.

    abstract：BACKGROUND:Radical prostatectomy (RP) can cure men with unfavorable intermediate- or high-risk prostate cancer (PC). However, some will experience short prostate-specific antigen (PSA) doubling time (PSADT) failure that requires additional treatment with increased toxicity. The present study investigated whether the gr...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2015.02.012

    authors： Cheney MD,Zhang D,Chen MH,Loffredo MJ,Richie JP,D'Amico AV

    更新日期：2015-08-01 00:00:00

  • The current and emerging role of immunotherapy in prostate cancer.

    abstract：:Recent phase III trial results have demonstrated the effectiveness of sipuleucel-T, a therapeutic cancer vaccine, in the treatment of metastatic prostate cancer. Yet, despite the survival benefit of sipuleucel-T, questions remain about how immunologic agents can be used in the treatment of metastatic prostate cancer. ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CGC.2010.n.002

    authors： Madan RA,Gulley JL

    更新日期：2010-12-01 00:00:00

  • Positive surgical margins after nephron-sparing surgery for renal cell carcinoma: incidence, clinical impact, and management.

    abstract：:Nephron-sparing surgery (NSS) for renal cell carcinoma (RCC) offers comparable oncologic results but a lower risk of chronic kidney disease when compared with radical nephrectomy; however it can result in positive surgical margins (PSMs) and consequently to a possible risk of oncologic failure. The aim of this review ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clgc.2012.09.010

    authors： Borghesi M,Brunocilla E,Schiavina R,Martorana G

    更新日期：2013-03-01 00:00:00

  • Role of Inflammation in the Perioperative Management of Urothelial Bladder Cancer With Squamous-Cell Features: Impact of Neutrophil-to-Lymphocyte Ratio on Outcomes and Response to Neoadjuvant Chemotherapy.

    abstract：BACKGROUND:Neutrophil-to-lymphocyte ratio (NLR) might reflect an increased neutrophilic inflammatory response, and urothelial tumors with squamous-cell features (SqD) have been linked to inflammation. We hypothesized that NLR could be prognostic in these patients. PATIENTS AND METHODS:In patients with SqD muscle-invas...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2017.01.024

    authors： Buisan O,Orsola A,Oliveira M,Martinez R,Etxaniz O,Areal J,Ibarz L

    更新日期：2017-08-01 00:00:00